Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy

Clinical Infectious Diseases

Volumn 57, Issue 2, 2013, Pages 290-297

  Fiscus, Susan A ^a   Cu Uvin, Susan ^b   Eshete, Abel Tilahun ^c   Hughes, Michael D ^c   Bao, Yajing ^c   Hosseinipour, Mina ^d   Grinsztejn, Beatriz ^e   Badal Faesen, Sharlaa ^f   Dragavon, Joan ^g   Coombs, Robert W ^g   Braun, Ken ^h   Moran, Laura ⁱ   Hakim, James ^j   Flanigan, Timothy ^b   Kumarasamy, N ^k   Campbell, Thomas B ^l  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^e Funda??o Oswaldo Cruz   (Brazil)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF WASHINGTON   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^k Center for AIDS Research and Education (YRG CARE)   (India)

^l UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

antiretroviral drugs; HIV 1 genital tract RNA; HIV 1 subtypes B and C

Indexed keywords

ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; SEMINAL PLASMA; SEX DIFFERENCE; VIROTHERAPY; VIRUS LOAD;

ANTIRETROVIRAL DRUGS; HIV-1 GENITAL TRACT RNA; HIV-1 SUBTYPES B AND C;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; GENITALIA, FEMALE; GENITALIA, MALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLASMA; RNA, VIRAL; VIRAL LOAD;

EID: 84879639521     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit195     Document Type: Article

References (26)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
2. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-10.
3. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
4. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-93.
5. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: Association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183: 206-12.
6. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352: 1510-4.
7. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-72.
8. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: A meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31:11-9.
9. Donnelly CA, Bartley LM, Ghani AC, et al. Gender difference in HIV-1 RNAviral loads. HIV Med 2005; 6:170-8.
10. Lingappa JR, Kahle E, Mugo N, et al., Partners HSV-2/HIV-1 Transmission Study Team. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the Partners study. PLoS One 2009; 4:e5272.
11. Grinsztejn B, Smeaton L, Barnett R, et al., PEARLS study team of the ACTG. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther 2011; 16:1057-62.
12. Günthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-27.
13. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-97.
14. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88:598-609.
15. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16:1149-67.
16. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type 1 infection in the genital tract of men and women. AIDS 2003; 17:455-80.
17. Dyer JR, Kazembe P, Vernazza PL, et al. High levels of human immuno-deficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998; 177:1742-6.
18. Neilson JR, John GC, Carr JK, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999; 73:4393-403.
19. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 2010; 24:573-82.
20. Novitsky V, Ndung'u T, Wang R, et al. Extended high viremics: A substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 2011; 25:1515-22.
21. Campbell TB, Smeaton LM, Kumarasamy N, et al., PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: A randomized clinical trial in diverse multinational settings. PLoS Med 2012; 9:e1001290.
22. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: A randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-8.
23. Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 2009; 23:479-83.
24. Baeten JM, Kahle E, Lingappa JR, et al., Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.
25. Cohen MS, Chen YQ, McCauley M, et al., HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
26. Los Alamos National Laboratory. HIV Sequence Database. http://www. hiv.lanl.gov/components/sequence/HIV/geo/geo.comp. Accessed 4 April 2013.